C3 treats first European patient with CellSpray
Friday, 28 October, 2005
Tissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has treated a first European patient with its burns therapy CellSpray at Halle, in Germany.
CellSpray is intended for use in patients with between 30 per cent and 90 per cent of injuries to the body surface. It was launched in Europe in September, at the European Burns Association meeting in Portugal. Surgeons and medical practitioners in 20 hospitals in German speaking countries have been trained in using the CellSpray technology.
In July, the first patient was treated with C3's CellSpray XP, which is intended for use in patients with injuries of 10 to 30 per cent of the body.
CellSpray is available for sale in Austria, Denmark, Germany, The Netherlands and the UK, while CellSpray XP is also available for sale in Switzerland and Italy.
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
Russia insists there is "no plague case" following lab worker death
Russian health authorities say there is no evidence that pneumonic plague played a part in the...
